> Concerned that they aren't addressing the different ways various ethnic groups respond to medication, researchers are mounting major efforts to recruit varied racial and ethnic groups for clinical trials. Report
> Actavis has been asked to pull out of the bidding for Merck KGaA's generic drug unit after submitting a bid a few hundred million euro below the offers of rivals, according to newspaper reports. Report
> Actavis is buying the drug Floxapen from GlaxoSmithKline. Report
> PTC Therapeutics has announced positive interim data from a Phase II clinical trial of PTC124 in patients with Duchenne muscular dystrophy due to a nonsense mutation. Release
> Chutes & Ladders: Joseph Zakrzewski, a 20-year veteran of Eli Lilly and former COO of Reliant Pharmaceuticals, has been named CEO of Xcellerex in Marlborough, MA. Release
And Finally… The Financial Times is reporting the MedImmune CEO David Mott could take home $400 million on the sale of the company to AstraZeneca. Report